Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 14/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.35 |
| ▸ | PDE1A | P54750 | 3/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610559 | 0.90 | PDE4A (0.39) | PDE9ATYK2PDE1CPDE1APDE1B | |
| SCHEMBL3609189 | 0.88 | PDE1C (0.39) | PDE9APDE1CPDE1APDE1B | |
| SCHEMBL3607708 | 0.86 | KHK (0.37) | PDE9ATYK2PDE1CPDE1APDE1B | |
| SCHEMBL5351035 | 0.86 | PRKDC (0.41) | PDE9APDE1CPDE1APDE1BMERTK | |
| SCHEMBL3602836 | 0.85 | MERTK (0.33) | PDE9ATYK2PDE1CPDE1APDE1B | |
| SCHEMBL3602702 | 0.85 | PDE1C (0.36) | PDE9APDE1CPDE1APDE1BMERTK | |
| SCHEMBL5346457 | 0.85 | PDE1C (0.33) | PDE9ATYK2PDE1CPDE1APDE1B | |
| SCHEMBL5452107 | 0.85 | MERTK (0.40) | PDE1CPDE1APDE1BMERTK | |
| SCHEMBL5357083 | 0.84 | PDE1C (0.35) | PDE9ATYK2PDE1CPDE1APDE1B | |
| SCHEMBL5361038 | 0.84 | PDE1C (0.36) | PDE9APDE1CPDE1APDE1BMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | claimed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE9A 11/4885TYK2 3537/4885PDE1C 22/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE9A 11/4885TYK2 3537/4885PDE1C 22/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE9A 11/4885TYK2 3537/4885PDE1C 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.